The requested information is provided below:<\/p>
<\/p>
<\/p>
Involuntary Redundancies September 2011 \u2013 June 2014, UK Regular Armed Forces Officers with 13-15 years of service<\/strong><\/p> Royal Navy<\/p><\/td> 10<\/p><\/td><\/tr> Army<\/p><\/td> 30<\/p><\/td><\/tr> Royal Air Force<\/p><\/td> 30<\/p><\/td><\/tr><\/tbody><\/table> <\/p> Notes: Figures for UK Regular Service Officers include Nursing Services, but exclude Full Time Reserve Service personnel, Gurkhas, mobilised Reservists, Military Provost Guard Service, Locally Engaged Personnel, Non Regular Permanent Staff, High Readiness Reserve and Expeditionary Forces Institute personnel. All figures are rounded to the nearest 10.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/1544", "label" : {"_value" : "Biography information for Lord Lancaster of Kimbolton"}
}
, "answeringMemberConstituency" : {"_value" : "Milton Keynes North"}
, "answeringMemberPrinted" : {"_value" : "Mark Lancaster"}
, "dateOfAnswer" : {"_value" : "2016-11-08", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2016-11-08T16:06:23.65Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "11"}
, "answeringDeptShortName" : {"_value" : "Defence"}
, "answeringDeptSortName" : {"_value" : "Defence"}
, "date" : {"_value" : "2016-11-02", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Armed Forces: Redundancy"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Defence, how many (a) Army, (b) Royal Air Force and (c) Royal Navy officers who had served for more than 12 but fewer than 16 years were made compulsorily redundant during the four tranches of redundancies from September 2011 to June 2014.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4433", "label" : {"_value" : "Biography information for Thangam Debbonaire"}
}
, "tablingMemberConstituency" : {"_value" : "Bristol West"}
, "tablingMemberPrinted" : [{"_value" : "Thangam Debbonaire"}
], "uin" : "51540"}
, {"_about" : "http://data.parliament.uk/resources/626585", "AnsweringBody" : [{"_value" : "Department for Education"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/626585/answer", "answerText" : {"_value" : " UK universities are home to both world-class teaching and life-changing research, and exiting the EU will not change this. The Government has already announced that EU students applying for a place at an English university or further education institution in 2017/2018 (or before) will continue to be eligible for student loans and grants for the duration of their course, even if the UK exits the EU during that period. To support research and innovation, we have also announced that HM Treasury will underwrite funding for approved Horizon 2020 projects applied for before the UK leaves the EU, including where specific projects continue beyond the UK\u2019s departure.<\/p> Future arrangements for EU students and staff, funding and also UK students studying abroad will need to be considered as part of wider discussions about the UK\u2019s relationship with the EU. The Government is fully committed to ensuring that we get the best possible outcome for the higher education sector from its negotiations with the EU.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4039", "label" : {"_value" : "Biography information for Lord Johnson of Marylebone"}
}
, "answeringMemberConstituency" : {"_value" : "Orpington"}
, "answeringMemberPrinted" : {"_value" : "Joseph Johnson"}
, "dateOfAnswer" : {"_value" : "2016-11-04", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2016-11-04T13:18:03.877Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "60"}
, "answeringDeptShortName" : {"_value" : "Education"}
, "answeringDeptSortName" : {"_value" : "Education"}
, "date" : {"_value" : "2016-11-01", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Universities: Competition"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Education, what steps she is taking to ensure that UK universities remain globally competitive after the UK leaves the EU.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4433", "label" : {"_value" : "Biography information for Thangam Debbonaire"}
}
, "tablingMemberConstituency" : {"_value" : "Bristol West"}
, "tablingMemberPrinted" : [{"_value" : "Thangam Debbonaire"}
], "uin" : "51362"}
, {"_about" : "http://data.parliament.uk/resources/626637", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/626637/answer", "answerText" : {"_value" : " The National Institute for Health and Care Excellence (NICE) is currently carrying out two separate technology appraisals of nivolumab (Opdivo) for previously treated locally advanced or metastatic non-squamous non-small cell lung cancer and previously treated locally advanced or metastatic squamous non-small-cell lung cancer after prior chemotherapy in adults.<\/p> <\/p> NICE is currently consulting on draft guidance for both appraisals and the closing date for comments is 4 November 2016. Subsequent timescales for guidance development are yet to be confirmed by NICE. NICE will publish comments received in response to the consultation and its responses alongside the next iteration of its draft guidance.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4019", "label" : {"_value" : "Biography information for Baroness Blackwood of North Oxford"}
}
, "answeringMemberConstituency" : {"_value" : "Oxford West and Abingdon"}
, "answeringMemberPrinted" : {"_value" : "Nicola Blackwood"}
, "dateOfAnswer" : {"_value" : "2016-11-04", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2016-11-04T10:38:53.477Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2016-11-01", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Nivolumab"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, pursuant to the Answer of 27 June 2014 to Question 40281, on what date he expects NICE to publish the results of the consultation on the guidance on the use of nivolumab for the treatment of lung cancer.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4433", "label" : {"_value" : "Biography information for Thangam Debbonaire"}
}
, "tablingMemberConstituency" : {"_value" : "Bristol West"}
, "tablingMemberPrinted" : [{"_value" : "Thangam Debbonaire"}
], "uin" : "51363"}
, {"_about" : "http://data.parliament.uk/resources/626753", "AnsweringBody" : [{"_value" : "Department for Business, Energy and Industrial Strategy"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/626753/answer", "answerText" : {"_value" : " The UK Patents Act 1977, in line with the WTO TRIPS Agreement, provides for compulsory licenses in certain circumstances.<\/p> <\/p> Kadcyla (trastuzumab emtansine) is currently available to patients in England for the treatment of HER2-positive locally advanced, unresectable or metastatic breast cancer through the Cancer Drugs Fund.<\/p> <\/p> The National Institute for Health and Care Excellence (NICE) is currently reviewing its technology appraisal guidance on trastuzumab emtansine for refractory, HER2 positive breast cancer. NICE expects to publish its updated guidance in February 2017.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4039", "label" : {"_value" : "Biography information for Lord Johnson of Marylebone"}
}
, "answeringMemberConstituency" : {"_value" : "Orpington"}
, "answeringMemberPrinted" : {"_value" : "Joseph Johnson"}
, "dateOfAnswer" : {"_value" : "2016-11-04", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2016-11-04T14:03:54.493Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "201"}
, "answeringDeptShortName" : {"_value" : "Business, Energy and Industrial Strategy"}
, "answeringDeptSortName" : {"_value" : "Business, Energy and Industrial Strategy"}
, "date" : {"_value" : "2016-11-01", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Intellectual Property: Drugs"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Business, Energy and Industrial Strategy, what his Department's policy is on using the flexibility provided by the Trade Related Aspects of Intellectual Property Rights under World Trade Organisation rules for compulsory license for the Kadcyla form of trastuzumab emtansine for UK patients.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4433", "label" : {"_value" : "Biography information for Thangam Debbonaire"}
}
, "tablingMemberConstituency" : {"_value" : "Bristol West"}
, "tablingMemberPrinted" : [{"_value" : "Thangam Debbonaire"}
], "uin" : "51439"}
], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 4, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}